Cramer’s Morning Thoughts: 20 Stocks to Watch

5. Eli Lilly and Company  (NYSE:LLY)

Number of Hedge Fund Investors: 100

According to the latest Morning Thoughts post, Eli Lilly’s Alzheimer’s drug, donanemab (brand name Kisunla), was approved in Japan for treating early symptomatic Alzheimer’s disease, marking Japan as the second major market to clear the drug after the U.S. in July.

“Eli Lilly ’s donanemab, brand name Kisunla, was approved in Japan for treating early symptomatic Alzheimer’s disease. Japan is the second major market to clear the drug following the U.S. in July.”

Eli Lilly and Company  (NYSE:LLY) is an attractive investment choice, driven by solid financial performance and a strong lineup of innovative drugs. In its Q2 2024 earnings report, Eli Lilly and Company  (NYSE:LLY) revealed revenue of $8.8 billion, a remarkable 17% increase from the previous year, along with a net income of $2.2 billion. This growth is largely fueled by the success of its diabetes and obesity treatments, especially Mounjaro, which is gaining popularity.

Eli Lilly and Company  (NYSE:LLY)’s diverse pipeline includes several promising drug candidates in key areas like oncology, immunology, and neuroscience, and positive results from clinical trials enhance its future potential. Eli Lilly and Company  (NYSE:LLY) has also formed strategic partnerships with biotech firms and research institutions, which boost its research and development efforts, allowing for faster introduction of new therapies.

Recent regulatory approvals for expanded uses of existing products further enhance Eli Lilly and Company (NYSE:LLY) market potential. Additionally, Eli Lilly and Company  (NYSE:LLY)’s commitment to sustainability and improving access to its medications aligns well with current healthcare trends. With a strong product portfolio and a focus on meeting important medical needs, Eli Lilly and Company  (NYSE:LLY) is well-positioned for ongoing growth in the competitive pharmaceutical market.